“Whether it’s our family, our friends, all of us are potentially patients one day.”
In a single sentence, Dr. Anthony Coyle, senior vice president and chief scientific officer at Pfizer’s Centers for Therapeutic Innovation (CTI), sums up what inspires the researchers and scientists fueling progress at America’s biopharmaceutical companies.
Collaboration for Cures
CTI’s unique model allows Pfizer scientists to work side-by-side with academia, patient foundations and the National Institutes of Health (NIH) to bridge the gap between early scientific discovery and its translation into new medicines. The research teams identify promising, early stage projects then collaborate to create and test potential new medicines.
While the road to scientific discovery is long and often full of set-backs, collaboration across the research and development ecosystem has the potential to make continual advancements – that ultimately lead to breakthrough discoveries – that much more efficient.
Through CTI’s network of 25 academic medical centers, five foundations, and the NIH, Pfizer is helping transform the traditional model of drug discovery in hopes that patients will realize the benefits of new life-changing and life-saving medicines even more quickly.
Learn more about the CTI and how this innovative approach translates into real progress and hope for patients.
Tina Stow Tina Stow previously served as Vice President of Communications at PhRMA. Prior to joining PhRMA in 2014, she spent more than a dozen years in corporate and agency communications and public affairs roles. A D.C. transplant via North Carolina and Georgia, Tina likes to travel, make the rounds to D.C.’s new restaurants, dote on her rescue labradoodle (Chloe), and complain about winter.
Topics: Research and Development, PhRMA Member Company, clinical research
Medicare Monday (100)
340B Spotlight (36)
Cost & Consequence (0)
